Literature DB >> 12640353

Oral citicoline treatment improves visual pathway function in glaucoma.

Robert Rejdak1, Jerzy Toczołowski, Jacek Kurkowski, Marek L Kamiński, Konrad Rejdak, Zbigniew Stelmasiak, Paweł Grieb.   

Abstract

BACKGROUND: Increased latency and reduced amplitude of visual evoked potentials (VEP), frequently encountered in ocular hypertension or open-angle glaucoma, suggest slowed neural conduction in the visual pathways. An improvement in VEP latency and amplitude has been reported following repeated intramuscular injections of citicoline, a neuroprotective drug. Our aim was to find whether citicoline given orally would produce a similar effect. MATERIAL/
METHODS: VEP latency and amplitude were measured in 21 glaucomatous eyes prior to and after two bi-weekly courses of citicoline taken orally in a dose of 1 gram/day. The treatment courses were separated by a two-week break; post-treatment VEP measurement was performed two weeks after the end of the second treatment.
RESULTS: 62% of the eyes showed a response to the treatment, with VEP latency reduced from 123.5 (3.9 SEM) ms to 111.9 (1.9 SEM) ms (P=0.0008), and VEP amplitude increased from 6.56 (1.39 SEM) to 7.88 (1.16 SEM) (P=0.04).
CONCLUSIONS: Citicoline given orally improves visual evoked potentials in some glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640353

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  23 in total

1.  Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up.

Authors:  Vincenzo Parisi
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

Review 2.  Potential neuroprotective biomolecules in ophthalmology.

Authors:  Mehrdad Afarid; Fatemeh Sanie-Jahromi
Journal:  Int Ophthalmol       Date:  2020-11-12       Impact factor: 2.031

Review 3.  Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.

Authors:  Elma E Chang; Jeffrey L Goldberg
Journal:  Ophthalmology       Date:  2012-02-18       Impact factor: 12.079

4.  The effects of glaucoma on the latency of the multifocal visual evoked potential.

Authors:  C Rodarte; D C Hood; E B Yang; T Grippo; V C Greenstein; J M Liebmann; R Ritch
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

5.  Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma.

Authors:  Asena Keles Sahin; Hasan Burhanettin Kapti; Aslihan Uzun
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

6.  Color Doppler imaging and pattern visual evoked potential in normal tension glaucoma and hypertension glaucoma.

Authors:  Yisheng Zhong; Yingjun Min; Ying Jiang; Yu Cheng; Jiao Qin; Xi Shen
Journal:  Doc Ophthalmol       Date:  2009-09-12       Impact factor: 2.379

7.  Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits.

Authors:  Zhengyu Song; Yuanyuan Gong; Haiyun Liu; Qiushi Ren; Xiaodong Sun
Journal:  Mol Vis       Date:  2011-08-04       Impact factor: 2.367

Review 8.  Senile Dementia and Glaucoma: Evidence for a Common Link.

Authors:  Sachin Jain; Ahmad A Aref
Journal:  J Ophthalmic Vis Res       Date:  2015 Apr-Jun

9.  Mapping cortical thickness of the patients with unilateral end-stage open angle glaucoma on planar cerebral cortex maps.

Authors:  Piotr Bogorodzki; Ewa Piątkowska-Janko; Jerzy Szaflik; Jacek Paweł Szaflik; Mira Gacek; Paweł Grieb
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

10.  Neuroprotective effects of citicoline in in vitro models of retinal neurodegeneration.

Authors:  Andrea Matteucci; Monica Varano; Lucia Gaddini; Cinzia Mallozzi; Marika Villa; Flavia Pricci; Fiorella Malchiodi-Albedi
Journal:  Int J Mol Sci       Date:  2014-04-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.